TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control on Metformin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Adult subjects between the ages of 18 to 75 years, inclusive~* Confirmed diagnosis of Type 2 diabetes mellitus~* Meet required laboratory values at screening, including fasting plasma glucose less than 270 mg/dL~* Stable dose of metformin monotherapy greater than 1500 mg/day for at least 8 weeks~* Willing and able to provide written informed consent~* Willing and able to maintain consistent dietary, physical activity, and sleeping patterns throughout the study~Exclusion Criteria:~* History of Type 1 diabetes mellitus, diabetic ketoacidosis, hyperosmolar nonketotic syndrome, or diabetes resulting from pancreatic disorder or secondary diabetes~* History of renal disease or clinically significant abnormal kidney function tests~* Presence of active hepatic disease or clinically significant abnormal liver function tests~* Subjects with a history of heart attack, severe/unstable angina, or coronary revascularization procedure within 6 months prior to study Day 1~* History of clinically significant cardiac arrhythmias within one year of study Day 1~* Subjects with congestive heart failure~* Subjects with uncontrolled Stage III hypertension~* Triglycerides \>1000 mg/dL at Screening~* Known history of HIV or hepatitis C~* History of illicit drug or alcohol abuse with one year of study Day 1~* Have had 2 or more emergency room visits, doctor visits, or hospitalizations due to hypoglycemia within 6 months of study Day 1~* Use of any other investigational drug within 30 days of study Day 1~* Prior exposure to LX4211~* Use of any medication or herbal supplement for the purpose of weight loss~* Chronic use of any antidiabetic therapy other than metformin in the 3 months prior to study Day 1~* Use of corticosteroids within 2 weeks prior to study Day 1~* Major surgery within 6 months of study Day 1~* Subjects with any history of severe gastroparesis~* Inability or difficulty swallowing whole capsules or tablets~* Women who are pregnant or breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Treatment A (Type: EXPERIMENTAL): None
- Treatment B (Type: EXPERIMENTAL): None
- Treatment C (Type: EXPERIMENTAL): None
- Treatment D (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Have participated in Kyowa Hakko Kirin Pharma, Inc.'s KRN23-INT-001 (NCT01340482) or KRN23-INT-002 (NCT01571596) studies (received at least 2 doses of KRN23)~2. Estimated glomerular filtration rate (eGFR) ≥ 60 mL/min or eGFR of 45 to \< 60 mL/min at Screening with confirmation that the renal insufficiency was not due to nephrocalcinosis.~3. Sexually active subjects must be willing to use an acceptable method of contraception (e.g., double barrier method) while participating in the study and for 30 days after receiving the last dose of KRN23.~Exclusion Criteria:~1. Subject experienced a safety-related event in the KRN23-INT-001 or KRN23-INT-002 study that, in the opinion of the investigator and sponsor, precludes resuming KRN23 treatment.~2. Presence of nephrocalcinosis on renal ultrasound that, in the opinion of the investigator and sponsor, precludes resuming KRN23 treatment.~3. Pregnant or breastfeeding at Screening or planning to become pregnant (self or partner) at any time during the study.~4. Participation in an investigational drug or device trial within 30 days of enrollment (other than KRN23-INT-001 or KRN23-INT-002).~5. Use of a pharmacologic vitamin D metabolite or analog (e.g., calcitriol, doxercalciferol, and paricalcitol), phosphate, or aluminum hydroxide antacids (e.g., Maalox® and Mylanta®) within 21 days prior to Screening or during the study.~6. Use of medication to suppress parathyroid hormone (PTH) (e.g., Sensipar®, cinacalcet, calcimimetics) within 2 months prior to Screening.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- KRN23 (Type: EXPERIMENTAL): KRN23 subcutaneous (SC) injections every 4 weeks. Starting doses will be based on the subject's last dose in study KRN23-INT-001 (NCT02312687) or KRN23-INT-002 (NCT01571596). Doses may be titrated to achieve the target peak serum phosphorus range.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PROtocol for Coxsackievirus VaccinE in Healthy VoluNTteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adults, males and females, ages 18 to 45 yrs, with BMI 19 to 30 kg/m2~* Women of childbearing potential must have negative pregnancy test and agree to use an acceptable method of highly effective contraceptive~* Men must either have a vasectomy or agree to use highly effective contraception~Exclusion Criteria:~* Prior or current clinically significant medical illness or disorder~* Has celiac disease or type 1 diabetes or related autoantibodies~* Has active acute or chronic/latent infection, or history of recent serious infection~* Recent acute illness or recent major illness, hospitalization or surgery~* Recent history of alcohol or drug abuse~* Received an experimental antibody or biologic therapy in last 6 months~* Received live, inactivated or subunit virus vaccine or a bacterial vaccine within last 4 weeks~* Intolerance or hypersensitivity to vaccines or vaccine components or has a drug or food allergy or allergic disease requiring medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1, Low Dose, Placebo (Type: PLACEBO_COMPARATOR): Low dose of placebo by intramuscular injection, 3 doses at 4-week intervals
- Cohort 1, Low Dose, PRV-101 (Type: EXPERIMENTAL): Low dose of PRV-101 by intramuscular injection, 3 doses at 4-week intervals
- Cohort 2, High Dose, Placebo (Type: PLACEBO_COMPARATOR): High dose of placebo by intramuscular injection, 3 doses at 4-week intervals
- Cohort 2, High Dose, PRV-101 (Type: EXPERIMENTAL): High dose of PRV-101 by intramuscular injection, 3 doses at 4-week intervals

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Efficacy & Safety Study of Esomeprazole Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With NSAID

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Medical history of gastric and/or duodenal ulcer~* A diagnosis of a chronic condition (rheumatoid arthritis, osteoarthritis, lumbago,etc) that requires daily NSAID use,at least 20 years of age~Exclusion Criteria:~* Having gastric or duodenal ulcer in active or healing stage according to the Sakita/Miwa classification~* History of esophageal, gastric or duodenal surgery~* Having severe liver disease or chronic renal disease

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): Placebo
- 2 (Type: EXPERIMENTAL): Esomeprazole 20 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Protective Effect of Mangafodipir Against Oxaliplatin Neurotoxicity

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* NCI CTC grade 2 or more neuropathy induced by oxaliplatine~* At least 18 years old~* ECOG PS: 2 or less~* Life expectancy longer than 3 months~* Written informed consent~* Adequate hematologic, liver and renal functions~Exclusion Criteria:~* Known hypersensibility to oxaliplatine~* Cancer resistant to oxaliplatine~* Fertile woman or man not willing to use adequate contraception~* Pregnant or lactating women~* Vitamin B6 administration within 48h prior to mangafodipir administration~* Uncontrolled infection~* Treatment with any other investigational agent, or participation in another clinical trial within 3 weeks prior to first administration of mangafodipir~* Evidence of any other disease or condition that contra-indicates the use of an investigational drug~* No Social Security insurance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Non-metastatic prostate cancer~* Men to receive Gonadotropin-releasing Hormone-agonist therapy~Exclusion Criteria:~* Other cancers except skin cancer~* Evidence of metabolic bone disease~* Prior use of bisphosphonates

- Gender: MALE
- Minimum Age: 55 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Risedronate (Type: EXPERIMENTAL): 35 mg by mouth every week as directed
- risedronate placebo tablet (Type: PLACEBO_COMPARATOR): Calcium and vitamin D

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction (Non-STEMI) Undergoing Percutaneous Coronary Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, \>18 to \<75 years of age~* Non ST-elevation myocardial infarction~* Woman of childbearing potential will be allowed only if using two acceptable methods of contraception~* Body mass index (BMI) \</= 40 kg/m2~Exclusion Criteria:~* Acute ST-elevation myocardial infarction (STEMI)~* Culprit coronary lesion with a total thrombotic occlusion or a lesion requiring the use of distal embolization protection or thrombectomy devices~* Percutaneous coronary intervention (PCI) within the past 72 hours~* Thrombolytic therapy within the past 7 days~* Major surgery within the past 3 months~* History of cerebral vascular disease or stroke in the past 3 months~* Bleeding disorders~* Inadequately controlled severe hypertension~* Prior coronary artery bypass graft (CABG) surgery~* Decompensated heart failure (oedema and/or rale)~* Acute infection at screening or active chronic infection within 3 months prior to PCI~* Patients known to be HIV positive, patients receiving antiretroviral drugs, or immuno-suppressed patients~* Uncontrolled diabetes mellitus (HbA1C \>10%) at baseline

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- 20 mg/kg RO4905417 before PCI (Type: EXPERIMENTAL): None
- 5 mg/kg RO4905417 before PCI (Type: EXPERIMENTAL): None
- Placebo before PCI (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Safety and Efficacy of Infliximab to Treat Hidradenitis Suppurtativa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Person must have moderate to severe Hidradenitis suppurativa~* Multiple ER or doctors visits related to HS~* Intralesional kenalog injection \>5/year, but none within 3 months of entry~* HS \>1 year duration~* Failed systemic retinoids, but not within 3 months of entry~* Failed at least one prior course of antibiotic therapy, which must not have been administered within 3 months of entry to the study (excluding the recommended antibiotic regimen given immediately before randomization for evidence of active infection~* History of surgery (reconstructive), but not within 3 months of entry~Exclusion Criteria:~* Women who are pregnant, nursing, or planning pregnancy within 6 months after the last infusion (this includes father's who plan on fathering a child within 6 months after their last infusion~* Known allergy against infliximab~* Use of other systemic anti-inflammatory medication except NSAIDs and low dose systemic steroids (equal or less than 10 mg daily prednisolone or equivalent).~* Have had any previous treatment with monoclonal antibodies or antibody fragments.~* Have a known history of serious infections (eg, hepatitis, pneumonia or pyelonephritis) in the previous 3 months.~* Have or have had an opportunistic infection (eg, herpes zoster \[shingles\], cytomegalovirus, Pneumocystis carinii, aspergillosis, histoplasmosis, or mycobacteria other than TB) within 6 months prior to screening.~* Are considered ineligible according to the TB eligibility assessment, screening, and early detection of reactivation rules defined in Section 26 on: Tuberculosis Eligibility Assessment, Screening, and Early Detection of Reactivation Rules.~* Have a history of lymphoproliferative disease, including lymphoma or signs suggestive of possible lymphoproliferative disease such as lymphadenopathy of unusual size or location (eg, nodes in the posterior triangle of the neck, infraclavicular, epitrochlear, or periaortic area), or splenomegaly.~* Currently have any known malignancy or have a history of malignancy within the previous 5 years, with the exception of basal cell or squamous cell carcinoma of the skin that has been fully excised with no evidence of recurrence.~* Have current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, or cerebral disease.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- infliximab (Type: EXPERIMENTAL): Double blind placebo cross-over
- Placebo (Type: PLACEBO_COMPARATOR): Double blind placebo controlled cross-over

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Older Adult Training Study With Creatine and CLA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy,~* Ambulatory,~* Recreationally active,~* Community dwelling~Exclusion Criteria:~* Evidence of coronary heart disease;~* Congestive heart disease;~* Uncontrolled hypertension;~* Chronic obstructive pulmonary disease;~* Diabetes mellitus;~* Renal failure;~* Major orthopedic disability; and~* Smoking

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Azithromycin for Lymphocytic Bronchiolitis/Bronchitis After Lung Transplantation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* Adult (age at least 18 years old at moment of transplantation)~* Able to take oral medication~* Histologic diagnosis of lymphocytic bronchiolitis or bronchitis ('grade B') without concurrent acute cellular allograft rejection 'grade A' ≥2~Exclusion Criteria:~* Severe suture problems (e.g. airway stenosis) requiring lasering or stenting

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Azithromycin (Type: EXPERIMENTAL): Add-on of study-drug (azithromycin) to 'standard of care': 250 mg daily for 5 days, followed by 250 mg every other day until the end of the study-period (6 months treatment).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effectiveness and Safety of Almotriptan Versus Placebo in the Treatment of Migraine Headache

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of migraine, with or without aura~* At least moderate pain with migraines~* Average of 2 to 6 migraines per month for past 3 months~* Duration of headache pain at least 4 hours~* Able to tell the difference between a migraine and a tension headache~* If taking a medication to prevent migraines, patients must have been taking a maintenance dose for at least 30 days before screening~* In generally good health~* If female, using birth control~Exclusion Criteria:~* Routinely experience other type of headache that might seem like a migraine headache~* An average of 15 or more headache days per month in the past 6 months~* Migraines began after age 50~* Taking \> 1 medicine for preventing migraines~* Use of any drugs on list of prohibited drugs, of opioid drugs in past 7 days, of corticosteroids in the past 30 days, of an investigational drug within 30 days~* Use of non-drug treatment for migraine in past 14 days unless have used this treatment for \> 14 days and plan to continue throughout study~* Overuse of medications that treat pain or nausea~* Migraine aura without headache~* Hemiplegic or basilar migraines~* Usually have vomiting with headache~* Headaches that usually occur upon waking~* Significant unstable medical disease~* Abnormal liver, kidney, blood, or ECG laboratory or test results~* Abusing drugs or alcohol~* History of a significant mental disorder~* Pregnant or breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Rumination by Biofeedback - a Randomized Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Rumination syndrome~Exclusion Criteria:~* Relevant organic disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Biofeedback (Type: EXPERIMENTAL): Abdomino-thoracic muscle activity after a challenge meal will be recorded by EMG and the signal will be displayed on a monitor in front of the patients; in the biofeedback group, patients will be instructed to control muscle activity.
- Placebo medication (Type: PLACEBO_COMPARATOR): Electromyography will be recorded but not shown to the patients. Patients will take a pill of placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Use of an Antiemetic to Shorten the Length of Labor in Nulliparous Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Primigravida~* Singleton pregnancy~* Term gestation i.e. 37- 42 weeks~* Sure reliable dates~* Vertex presentation, occipitoanterior position~* Spontaneous onset of labor~* Regular uterine contractions at every 5 min ,each lasting for 20 sec~* Cervical dilatation of 3-5cm~* With or without rupture of membranes~* No evidence of maternal or fetal distress~Exclusion Criteria:~* Mal-presentations~* Mal-positions~* Multifetal pregnancy~* Cephalopelvic disproportion~* history of cervical surgery or injury~* Hypersensitivity to metoclopramide

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Metoclopramide (Type: ACTIVE_COMPARATOR): Intravenous injection of 10mg metoclopramide
- Placebo (Type: PLACEBO_COMPARATOR): Intravenous injection of 0.9% sodium chloride

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy of Elderly Patients With Non-Small-Cell Lung Cancer (NSCLC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologically / cytologically proven NSCLC stage IIIB or IV~* age \>= 70 years old and \< 90 years old

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): Chemotherapy (mono)
- B (Type: EXPERIMENTAL): Chemotherapy (doublet)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete